Acute Myeloid Leukemia Real World Treatment Patterns
- Status
- WITHDRAWN
- Phase
- N/A
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
- Status
- RECRUITING
- Phase
- PHASE3
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE3
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2